GlassScriptPhysician profile
Thomas C Winegarden
NPI 1194707828
$55,158.46
in general payments reported to CMS, 2019-2025
28 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $6,194 · 2021: $1,957 · 2022: $1,206 · 2023: $101 · 2024: $15K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,130 · Travel and Lodging: $1,698 · Food and Beverage: $1,281 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,735.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,130.00 |
| Travel and Lodging | $1,697.65 |
| Food and Beverage | $1,280.57 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31,209.32 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $7,973.63 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $7,867.50 | 2019-2021 | |
| Allergan, INC. | $4,933.33 | 2019-2020 | |
| Abbvie INC. | $1,141.87 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $1,061.77 | 2020 | |
| Lundbeck LLC | $121.12 | 2019-2025 | Rexulti, Brintellix |
| Neuronetics, INC. | $116.20 | 2019-2025 | Neurostar Tms Therapy System |
| Supernus Pharmaceuticals, INC. | $76.14 | 2024-2025 | Qelbree |
| Alkermes, INC. | $75.08 | 2019-2023 | Vivitrol |
| Vanda Pharmaceuticals INC. | $70.80 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.75 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $62.90 | 2022-2025 | Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $55.05 | 2019-2024 | |
| Sage Therapeutics, LLC | $49.45 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $38.52 | 2019 | |
| Indivior INC. | $33.59 | 2024 | Sublocade |
| Tris Pharma INC | $33.54 | 2023-2024 | Dyanavel Xr |
| Tempus Ai, INC | $28.65 | 2024 | |
| Almatica Pharma LLC | $27.97 | 2022 | |
| Eisai INC. | $20.48 | 2020 | |
| Lilly USA, LLC | $15.56 | 2025 | Zepbound |
| Vertical Pharmaceuticals, LLC | $14.84 | 2019 | |
| Novo Nordisk INC | $14.62 | 2025 | Wegovy |
| Collegium Pharmaceutical, INC. | $14.52 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $12.36 | 2019 | |
| Brainsway USA INC | $11.14 | 2019 | |
| Corium, LLC | $9.76 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Winegarden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.